Tectonic Therapeutics Appoints Dr. François Nader As Chair And Independent Director Of Its Board Of Directors

Tectonic Therapeutic, Inc., a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs), announced the appointment of François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026. Upon joining the board, Dr. Nader will also assume the role of Chair of the Board. He succeeds Terry McGuire, who will resign from the Chair position but remain a board member until Tectonic’s 2026 Annual Meeting of Stockholders, anticipated in June 2026, to ensure a smooth leadership transition.

Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industries. He currently serves as an Independent Director at Moderna, Inc., where he chairs both the Talent & Compensation Committee and the Nominating & Governance Committee. Throughout his career, Dr. Nader has held executive and board roles at numerous biotechnology companies, contributing to major strategic transactions, including the acquisitions of Acceleron Pharma by Merck, Alexion Pharmaceuticals by AstraZeneca, Prevail Therapeutics by Eli Lilly, Clementia Pharmaceuticals by Ipsen, Advanced Accelerator Applications by Novartis, Baxalta by Shire, NPS Pharmaceuticals by Shire, and Noven Pharmaceuticals by Hisamitsu. 

He also served as President and Chief Executive Officer of NPS Pharmaceuticals, leading the company’s transformation into a global leader in rare disease therapies, and held senior leadership roles spanning medical, regulatory, and commercial functions at Aventis and its predecessor companies. Dr. Nader earned his Doctorate in Medicine from St. Joseph University in Lebanon and a Physician Executive MBA from the University of Tennessee.

Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic, welcomed Dr. Nader to the board, noting his exceptional leadership experience, deep expertise in corporate governance and strategic transactions, and strong record in building and scaling innovative biotechnology companies. She emphasized that his perspective will be instrumental as Tectonic continues advancing its GPCR-targeted pipeline and positioning the company for long-term growth and shareholder value. Dr. Reicin also expressed gratitude to Terry McGuire for his leadership and contributions since Tectonic’s inception, recognizing his role in helping build the company.

Dr. Nader stated that he is excited to join Tectonic at this critical stage of development. He highlighted the company’s approach to GPCR biology as having the potential to unlock meaningful therapeutic advances and said he looks forward to collaborating with the board and management to guide Tectonic’s strategy and support its continued growth. Terry McGuire also expressed strong support for Dr. Nader’s appointment, reflecting on his own tenure as Chair and his pride in contributing to the company’s progress in developing innovative GPCR-targeted therapies for patients with serious diseases.

With this leadership transition, Tectonic Therapeutic strengthens its board with deep industry experience and strategic insight, positioning the company to advance its pipeline of GPCR-focused therapeutics and drive future innovation and growth.